GI Innovation signed a contract with Medirama for joint research development of next generation innovative immuno-oncology

-GI Innovation-Medirama forms a ‘Joint Development Committee’ for professionalism maximization

-Joint development for two new immuno-oncology… partial shared cooperative model of commercialization revenue

GI Innovation, an innovative new drug development company signed a contract with Medirama, clinical development specialized company for joint research development of next generation innovative immuno-oncology.

The contract that have been signed on 7th and have progressed quickly to start a new immuno-oncology development MOU in September and each company will cooperate for joint development of next generation immuno-oncology and commercialization.  In particular, they will share the progress periodically to organize ‘Joint Development Committee(JDC)’ through establishing effective joint research plans and periodical conferences based on each company’s expertise.

Through the JDC it will maximize synergy according to a full cycle of immuno-oncology development ?discovery of candidate material ?non-clinical/clinical development ?strategies of commercialization, etc.

In particular, this contract will progress with cooperation model that jointly develops two cases of immuno-oncology, including new bispecific fusion protein of GI Innovation and will share partial revenue after commercialization.

GI Innovation licensed out main pipeline, immuno-oncology GI-101 (Simcere China) and allergic disease treatment GI-301 (Yuhan Pharm.) in non-clinical stage value of 2.3 trillion won and currently each pipeline is progressing global clinical 1/2 phase and domestic clinical 1 phase.

In particular, GI Innovation recently unveiled the progress of KEYNOTE-B59 clinical research on GI-101 in SITC 2021. 

As of yet, GI-101 clinical trial has finished dosing enrolled patients in cohort 2 without dose-limiting toxicities (DLTs) and will launch a cohort combined with Keytruda of MSD soon. 

In addition, GI Innovation has passed the technical evaluation to Unicorn track (special listing track of market evaluation excellent company) for KOSDAQ listing and is facing to file a preliminary application to go public on KRX.

Medirama is a CDRO (Clinical Development and Research Organization) and supplies clinical development platform that progresses clinical designs and clinical developments of candidates for new drug development companies.